本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗,我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示,便表示您已接受我們的網站使用條款。 關閉
SINGAPORE, March 31, 2023 /PRNewswire/ -- LightInTheBox Holding Co., Ltd. (NYSE: LITB) ("LightInTheBox" or the "Company"), a global online retail company that delivers products directly to consumers around the world, today announced that it has filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2022 with the U.S. Securities and Exchange Commission ("SEC"). An electronic copy of the annual report on Form 20-F can be accessed on LightInTheBox's investor relations website at https://ir.lightinthebox.com and on the SEC's website at https://www.sec.gov. Shareholders may receive a hard copy of LightInTheBox's audited financial statements for the fiscal year ended December 31, 2022 free of charge upon request. Requests should be submitted to ir@lightinthebox.com. About LightInTheBox Holding Co., Ltd. LightInTheBox is a global online retail company that delivers products directly to consumers around the world. The Company offers customers a convenient way to shop for a wide selection of products at attractive prices through its www.lightinthebox.com, www.miniinthebox.com, www.ezbuy.sg and other websites and mobile applications, which are available in over 20 major languages and cover more than 140 countries. For more information, please visit www.lightinthebox.com. Investor Relations Contact ChristensenMs. Xiaoyan SuTel: +86 (10) 5900 1548Email: ir@lightinthebox.com OR ChristensenMs. Linda BergkampPhone: +1-480-614-3004Email: linda.bergkamp@christensencomms.com
SHANGHAI, March 28, 2023 /PRNewswire/ -- Trip.com Group Limited (Nasdaq: TCOM; HKEX: 9961) ("Trip.com Group" or the "Company"), a leading one-stop travel service provider of accommodation reservation, transportation ticketing, packaged tours and corporate travel management, today announced that the Company has filed its annual report on Form 20-F that includes its audited financial statements for three years ended December 31, 2022 with the Securities and Exchange Commission on March 27, 2023. The annual report is available on the Company's website at https://investors.trip.com. Holders of the Company's securities may request a copy of the Company's annual report free of charge according to the instructions provided on the Company's website. About Trip.com Group Limited Trip.com Group Limited (Nasdaq: TCOM; HKEX: 9961) is a leading global one-stop travel platform, integrating a comprehensive suite of travel products and services and differentiated travel content. It is the go-to destination for travelers in China, and increasingly for travelers around the world, to explore travel, get inspired, make informed and cost-effective travel bookings, enjoy hassle-free on-the-go support, and share travel experience. Founded in 1999 and listed on Nasdaq in 2003 and HKEX in 2021, the Company currently operates under a portfolio of brands, including Ctrip, Qunar, Trip.com and Skyscanner, with the mission "to pursue the perfect trip for a better world." For further information, please contact: Investor RelationsTrip.com Group Limited Tel: +86 (21) 3406-4880 X 12229Email: iremail@trip.com
AD HOC ANNOUNCEMENT pursuant to Art. 53 Listing Rules of SIX Swiss Exchange ZURICH, March 15, 2023 /PRNewswire/ -- The Adecco Group 2022 Annual Report is now available in the Ad Hoc section of the Group's website. Please also refer to the dedicated Annual Report section. 2022 Annual Report (PDF) Financial calendar AGM 12 April 2023 Ex-Dividend date 18 April 2023 Q1 2023 Results 4 May 2023 Q2 2023 / Half Year 2023 Results 3 August 2023 Q3 2023 Results 2 November 2023 About The Adecco Group The Adecco Group is the world's leading talent company. Our purpose is making the future work for everyone. Through our three global business units - Adecco, Akkodis and LHH - across 60 countries, we enable sustainable and lifelong employability for individuals, deliver digital and engineering solutions to power the Smart Industry transformation and empower organisations to optimise their workforces. The Adecco Group leads by example and is committed to an inclusive culture, fostering sustainable employability, and supporting resilient economies and communities. The Adecco Group AG is headquartered in Zurich, Switzerland (ISIN: CH0012138605) and listed on the SIX Swiss Exchange (ADEN). Important notice about forward-looking informationInformation in this release may involve guidance, expectations, beliefs, plans, intentions or strategies regarding the future. These forward-looking statements involve risks and uncertainties. All forward-looking statements included in this release are based on information available to Adecco Group AG as of the date of this release, and we assume no duty to update any such forward-looking statements. The forward-looking statements in this release are not guarantees of future performance and actual results could differ materially from our current expectations. Numerous factors could cause or contribute to such differences. Factors that could affect the Company's forward-looking statements include, among other things: global GDP trends and the demand for temporary work; the impact of the global outbreak of novel coronavirus disease (COVID); changes in regulation of temporary work; intense competition in the markets in which the Company operates; integration of acquired companies; changes in the Company's ability to attract and retain qualified internal and external personnel or clients; the potential impact of disruptions related to IT; any adverse developments in existing commercial relationships, disputes or legal and tax proceedings. For further information please contact: Investor Relations investor.relations@adeccogroup.com +41 (0)44 878 88 88 Press Office media@adeccogroup.com +41 (0)44 878 87 87
Turin, 2nd March 2023. Iveco Group N.V. (MI: IVG) announced that it filed today its 2022 Annual Report with the Netherlands Authority for the Financial Markets (AFM) in European Single Electronic Format (ESEF). The document is available in the Investors section of the Iveco Group corporate website at www.ivecogroup.com. Iveco Group’s Annual Report for the year ended 31st December 2022 will be on the agenda of the Annual General Meeting of its Shareholders (AGM), that will be held in Amsterdam on 14th April 2023 at 11:30 a.m. CEST. In addition, the agenda of the AGM includes the discussion of the Company’s dividend policy, the remuneration report (advisory voting only), the granting of discharge to the members of the Board, the re-appointment of the Executive and Non-Executive Directors, the authorization to the Board to acquire Common Shares in the Company. The Notice of the AGM, the Agenda and the relevant Explanatory Notes, the instructions for voting, and other AGM materials were also published today and are available on the Company’s website at www.ivecogroup.com, where they can be viewed and downloaded. Iveco Group N.V. (MI: IVG) is the home of unique people and brands that power your business and mission to advance a more sustainable society. The eight brands are each a major force in its specific business: IVECO, a pioneering commercial vehicles brand that designs, manufactures, and markets heavy, medium, and light-duty trucks; FPT Industrial, a global leader in a vast array of advanced powertrain technologies in the agriculture, construction, marine, power generation, and commercial vehicles sectors; IVECO BUS and HEULIEZ, mass-transit and premium bus and coach brands; IDV, for highly-specialised defence and civil protection equipment; ASTRA, a leader in large-scale heavy-duty quarry and construction vehicles; MAGIRUS, the industry-reputed firefighting vehicle and equipment manufacturer; and IVECO CAPITAL, the financing arm which supports them all. Iveco Group employs approximately 34,000 people around the world and has 28 manufacturing plants and 29 R&D centres. Further information is available on the Company’s website www.ivecogroup.com Media Contacts: Francesco Polsinelli, Mob: +39 335 1776091 Fabio Lepore, Mob: +39 335 7469007 E-mail: mediarelations@ivecogroup.com Investor Relations: Federico Donati, Tel: +39 011 0073539 E-mail: investor.relations@ivecogroup.com
STOCKHOLM, Feb. 23, 2023 /PRNewswire/ -- AB Electrolux Annual Report for 2022 has been published on the Group's website as of today. The Annual Report in Swedish as well as an English translation are available on www.electroluxgroup.com in pdf-format and will be distributed in mid-March 2023 to shareholders who have requested it. The Swedish Annual Report is also available on the Group's website in European Single Electronic Format (ESEF). This disclosure contains information that AB Electrolux is obliged to make public pursuant to the Swedish Securities Markets Act (2007:528). The information was submitted for publication, through the agency of the contact person, on 23-02-2023 08:00 CET. For further information, please contact:Sophie Arnius, Investor Relations, +46 70 590 80 72Electrolux Group Press Hotline, +46 8 657 65 07 The following files are available for download: https://mb.cision.com/Main/1853/3720873/1866059.pdf Annual Report 2022
中國上海和美國馬薩諸塞州劍橋2024年11月21日 /美通社/ -- 再鼎醫藥(以下簡稱「再鼎醫藥」,納斯達克股票代碼:ZLAB;香港聯交所股份代號:9688 )和輝瑞(以下簡稱「輝瑞」,NYSE: PFE)今日宣布,雙方就新型抗菌藥物鼎優樂®(舒巴坦鈉-度洛巴坦鈉)達成在中國內地的戰略合作,由輝瑞旗下公司獨家負責該產品在中國內地的相關商業化運營。通過此次合作,再鼎醫藥將借助輝瑞旗下公司在抗感染領域行業領先的商業化能力以助力中國有需要的患者能夠更快獲得這一重要療法。雙方關於該進口產品的合作期限至 2028年11月,受限於提前終止或延長。 新型抗菌藥物鼎優樂®是目前唯一專門為治療碳青霉烯類耐藥的鮑曼不動桿菌(CRAB)而開發的抗菌藥物[1]。該產品於2023年、2024年分別在美國和中國內地獲批,用於治療由鮑曼-醋酸鈣不動桿菌復合體敏感分離株引起的成人患者的醫院獲得性細菌性肺炎和呼吸機相關性細菌性肺炎(HABP/VABP)。美國疾病控制與預防中心(CDC)已將耐碳青霉烯類微生物確定為緊迫威脅[2]。在全球范圍內,鮑曼不動桿菌是2019年因耐藥性致死的六大主要病原體之一[3]。2024年,世界衛生組織發布的細菌重點病原體清單中,CRAB被認為是對公共衛生構成最嚴重威脅的抗生素耐藥的細菌病原體之一,列入關鍵優先級組[4]。在中國,鮑曼不動桿菌也是細菌耐藥性導致死亡的主要原因之一[5]。根據全國細菌耐藥監測網2022年年度報告,中國內地約有30萬例鮑曼不動桿菌株檢出報告[6]。在鼎優樂® 獲批之前,由CRAB感染引起的HABP/VABP的治療方案非常有限,缺乏治療CRAB感染的金標准療法[7]。 再鼎醫藥總裁兼首席運營官Josh Smiley表示:「鮑曼不動桿菌耐藥日趨嚴重,危重症患者臨床死亡率高、預後差,造成嚴重的疾病負擔。最新監測數據顯示,中國鮑曼不動桿菌對碳青霉烯類抗生素的耐藥率已升至約74%[8]。再鼎醫藥在鼎優樂的研發過程中發揮了重要作用,使該藥物於今年早些時候在中國獲得批准。通過與輝瑞的合作,我們希望能更快地為中國患者提供這一創新療法,助力挽救危重患者的生命。」 輝瑞中國區總裁Jean-Christophe Pointeau表示,「輝瑞在抗感染領域深耕多年。我們始終致力於『為患者帶來改變其生活的突破創新』,以應對細菌、真菌、病毒等多種微生物感染的挑戰,減少患者疾病負擔。此次與再鼎醫藥的合作,雙方將攜手對抗鮑曼不動桿菌治療中日益嚴重的耐藥問題,盡快滿足患者未被滿足的臨床治療需求,體現醫藥企業的新質生產力,助力'健康中國'目標的實現。」 關於鼎優樂®(舒巴坦鈉-度洛巴坦鈉) 靜脈輸注型組合藥物鼎優樂®(舒巴坦鈉-度洛巴坦鈉)由Entasis Therapeutics Inc.(Innoviva Specialty Therapeutics子公司)開發,是由舒巴坦鈉(一種β-內酰胺類抗生素)和度洛巴坦鈉(一種β-內酰胺酶抑制劑)組合而成。舒巴坦鈉-度洛巴坦鈉於2023年、2024年分別由美國食品藥品監督管理局和中國國家藥品監督管理局批准,用於治療由鮑曼-醋酸鈣不動桿菌復合體敏感分離株引起的18歲及以上患者的醫院獲得性細菌性肺炎和呼吸機相關性細菌性肺炎(HABP/VABP)。 舒巴坦鈉-度洛巴坦鈉在中國獲批是基於ATTACK研究(NCT03894046)的積極結果,該研究是一項全球3期注冊性研究,評估了舒巴坦鈉-度洛巴坦鈉v.s.多粘菌素E用於治療鮑曼不動桿菌感染患者的安全性和有效性。在該研究中,舒巴坦鈉-度洛巴坦鈉在研究主要終點,即碳青霉烯類耐藥不動桿菌感染患者的28天全因死亡率方面,與多粘菌素E相比具有統計學上的非劣效性,並且在臨床治愈率方面有顯著提升。舒巴坦鈉-度洛巴坦鈉具有良好的耐受性,並在整個臨床研究項目中均表現出良好的安全性特征。再鼎醫藥參與了ATTACK全球研究,在中國招募患者。中國患者隊列數據證實了全球研究中關於死亡率和臨床應答改善的結果。 再鼎醫藥由Entasis Therapeutics Inc.授權擁有在大中華區(中國內地、香港、台灣地區和澳門)、韓國、越南、泰國、柬埔寨、老撾、馬來西亞、印度尼西亞、菲律賓、新加坡、澳大利亞、新西蘭和日本開發和商業化舒巴坦鈉-度洛巴坦鈉的獨占許可。 關於再鼎醫藥 再鼎醫藥(納斯達克股票代碼:ZLAB;香港聯交所股份代號:9688)是一家以研發為基礎、處於商業化階段的創新型生物制藥公司,總部位於中國和美國。我們致力於通過創新產品的發現、開發和商業化解決腫瘤、自身免疫性疾病、感染性疾病和中樞神經系統疾病領域未被滿足的巨大醫療需求。我們的目標是利用我們的能力和資源努力促進中國及全世界人類的健康福祉。有關再鼎醫藥的更多信息,請訪問www.zailaboratory.com或關注公司官微:再鼎醫藥。 再鼎醫藥前瞻性聲明 本新聞稿包含關於再鼎醫藥未來預期、計劃和展望的前瞻性陳述,包括但不限於與我們關於鼎優樂的商業化計劃、鼎優樂的潛在裨益,以及在中國內地治療鮑曼不動桿菌(包括碳青霉烯類耐藥的不動桿菌菌株)引起的某些感染的潛在療法。該等前瞻性陳述可能包含諸如「旨在」、「預計」、「認為」、「有可能」、「估計」、「預期」、「預測」、「目標」、「打算」、「可能」、「計劃」、「可能的」、「潛在」、「將」、「將會」等詞匯和其他類似表述。該等陳述構成《1995年美國私人證券訴訟改革法案》中定義的「前瞻性陳述」。前瞻性陳述並非對過往事實的陳述,亦非對未來表現的擔保或保證。前瞻性陳述基於我們截至本新聞稿發布之日的預期和假設,並且受到固有不確定性、風險以及可能與前瞻性陳述所預期的情況存在重大差異的情勢變更的影響。實際結果可能受各種重要因素的影響而與前瞻性陳述所示存在重大差異,這些因素包括我們向美國證券交易委員會(SEC)提交的最近的年報和季報以及其他報告中指出的因素。該等報告可以在公司網站 www.zailaboratory.com 或SEC網站www.sec.gov查閱。除法律要求之外,不論是出於新信息、未來事件或其他原因,我們均無義務更新或修訂任何前瞻性陳述。該等前瞻性陳述不應被視為我們在本新聞稿發布之日後任何日期的意見而加以信賴。 關於輝瑞:為患者帶來改變其生活的突破創新 在輝瑞,我們通過科學和全球資源為人們提供治療方案,以延長其生命,顯著改善其生活。在醫療衛生產品的探索、研發和生產過程中,輝瑞始終致力於奉行嚴格的質量、安全和價值標准。我們在全球的產品組合包括創新藥品和疫苗。每天,輝瑞在發達和新興市場的員工都在推進人類健康,推動疾病的預防、治療和治愈,以應對挑戰我們這個時代的頑疾。輝瑞還與醫療衛生服務方、政府和社區合作,支持並促進世界各地的人們能夠獲得更為可靠和可承付的醫療衛生服務。這與輝瑞作為一家全球卓越的創新生物制藥公司的責任是一致的。175年來,輝瑞一直致力於為所有依賴我們的人帶來改變。如需了解更多信息,請登錄www.pfizer.com.cn。 輝瑞免責聲明 本新聞稿中所含信息僅截至2024年11月21日。不管是由於新信息、未來事件還是進展,輝瑞一概不承擔對該新聞稿的前瞻性聲明進行更新的義務。 本發布含有關於輝瑞和再鼎醫藥就新型抗菌藥物鼎優樂®在中國大陸地區的戰略合作以及輝瑞為解決多種微生物感染的挑戰所做努力的前瞻性信息,包括其潛在益處,這些信息涉及到重大的風險和不確定性,可能導致實際結果與這些聲明所表達或暗示的結果存在實質性的差異。風險和不確定性包括但不限於:實現戰略合作預期收益的能力相關風險,包括戰略合作預期收益無法實現或無法在預期時間內實現的可能性;鼎優樂®是否能成功商業化;監管機構對於產品標簽、生產過程、安全性和/或其他事項的決定,可能影響鼎優樂®產品供應情況或其商業潛力;COVID-19對輝瑞業務、運營和財務結果的影響所帶來的不確定性;以及市場競爭發展帶來的不確定性。 關於風險和不確定性的更多描述可在涵蓋截至2023年12月31日財年的輝瑞年報10-K報告中找到,並在後續的10-Q報告中更新,包括在標題為「風險因素」和「前瞻性信息及可能影響未來結果的因素」的章節中,以及其後續的8-K報告中,所有這些報告均已提交至美國證券交易委員會,可在www.sec.gov 和www.pfizer.com查閱。 參考文獻: (1) El-Ghali A, Kunz Coyne AJ, Caniff K, Bleick C, Rybak MJ. Sulbactam-durlobactam: A novel β-lactam-β-lactamase inhibitor combination targeting carbapenem-resistant Acinetobacter baumannii infections. Pharmacotherapy. 2023;43(6):502-513. doi:10.1002/phar.2802(2) Centers for Disease Control and Prevention, "Carbapenem-resistant Acinetobacter baumannii (CRAB): An urgent public health threat in United States healthcare facilities," August 2021: https://arpsp.cdc.gov/story/cra-urgent-public-health-threat(3) Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022; 399(10325):629-655. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02724-0/fulltext(4) WHO Bacterial Priority Pathogens List, 2024(5) Zhang C, Fu X, Liu Y, Zhao H, Wang G. Burden of infectious diseases and bacterial antimicrobial resistance in China: a systematic analysis for the global burden of disease study 2019. Lancet Reg Health West Pac. 2023;43:100972. Published 2023 Nov 22. doi:10.1016/j.lanwpc.2023.100972(6) 2022 Annual Report of China Antimicrobial Resistance Surveillance System (CARSS)(7) Zhang S, Di L, Qi Y, Qian X, Wang S. Treatment of infections caused by carbapenem-resistant Acinetobacter baumannii. Front Cell Infect Microbiol. 2024;14:1395260. Published 2024 Jul 18. doi:10.3389/fcimb.2024.1395260(8) 2023 Annual Report of China Antimicrobial Surveillance Network (CHINET)
A12 藝術空間
2022 Annual Report
請先登入後才能發佈新聞。
還不是會員嗎?立即 加入台灣產經新聞網會員 ,使用免費新聞發佈服務。 (服務項目) (投稿規範)